Ex-Al­ler­gan CMO takes the helm at Lewis Cant­ley's metas­ta­sis-fo­cused biotech start­up

Al­ler­gan’s for­mer top team is mov­ing on­to new ad­ven­tures as Ab­b­Vie ex­ecs take di­rect con­trol of their shop.

Just days af­ter Brent Saun­ders pitched a $460 mil­lion SPAC for his next big move, his chief med­ical of­fi­cer is tak­ing up the CEO post at a biotech start­up out of New York.

For Charles Hugh-Jones, the role at Volas­tra Ther­a­peu­tics brings him back to a nar­row fo­cus on on­col­o­gy, an area he’s spe­cial­ized in through­out his years at Scher­ing/Bay­er, Sanofi, and even­tu­al­ly Pfiz­er. But in­stead of over­see­ing late-stage de­vel­op­ment, he is fac­ing the chal­lenge of bring­ing some ear­ly-stage drug can­di­dates for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER